Results 51 to 60 of about 23,538 (242)
Transcytosis and adhesion assays of HBMEC.
(A) HBMEC transcytosis assay. Mechanistic confirmatory results of mutants 4H12 and 7F4. Yeast cell numbers of C. neoformans mutants and parental strain CMO18 in lower chamber of transcytosis assay at different time point (1 hr, 3 hrs, and 6 hrs) are ...
Michael S. Price (157943) +9 more
core +1 more source
The low permeability of nanoparticles (NPs) across the intestinal epithelium remains a major challenge for their application of delivering macromolecular therapeutic agents via the oral route.
Ruiying Li +5 more
doaj +1 more source
We developed a patient‐derived, functional microfluidic model of the diffuse midline glioma (DMG) blood–brain–tumor barrier (BBTB) comprised of endothelial cells, astrocytes, pericytes, and tumor cells. The system forms perfusable microvasculature, reveals the BBTB retains vascular integrity, identifies DMG‐specific transcriptomic changes distinct from
Kimberly R. Bennett +7 more
wiley +1 more source
Probiotic Spore Inspired Oral Drug Delivery System With Multiple-Barriers-Crossing Ability Modulates Gut-Brain Axis for Parkinson's Disease Therapy. [PDF]
Inspired by the germination of probiotic spores, we utilize the excellent characteristics of spores to break through multiple barriers of oral brain‐targeted delivery. Besides the probiotics mediated gut‐brain communication, the spore coat proteins derived nanosystems with multiple‐barriers‐crossing ability alleviate neurodegeneration.
Feng Q +9 more
europepmc +2 more sources
Conventional therapies suffer from poor blood–brain barrier (BBB) penetration and disordered ion/reactive oxygen species (ROS) homeostasis, hindering precise neurological treatment. Electrochemical strategies achieve accurate spatiotemporal regulation of neural homeostasis.
Xiaokang Hu +5 more
wiley +1 more source
Strategies for Targeted Delivery of Exosomes to the Brain: Advantages and Challenges
Delivering therapeutics to the central nervous system (CNS) is difficult because of the blood–brain barrier (BBB). Therapeutic delivery across the tight junctions of the BBB can be achieved through various endogenous transportation mechanisms.
Hojun Choi +6 more
doaj +1 more source
Preparation of RVG‐modified erythrocyte membrane‐coated HMPB nanocarriers loaded with L‐arginine and NBP (RM@HPAN) and its neuroprotective mechanism. After intravenous injection, RM@HPAN achieves prolonged circulation, RVG‐29‐mediated BBB penetration, and ischemic accumulation.
Shaofa Li +9 more
wiley +1 more source
This study demonstrates that Tf‐PDA NPs combine a receptor‐mediated targeting with mild photothermal activation to enhance nanoparticle accumulation in the brain. NIR‐activated Tf‐PDA NPs increase BBB permeability to NPs in vitro and in vivo without inducing cytotoxicity or adverse immune responses.
Rafaela Ferrão +5 more
wiley +1 more source
CNS Delivery Via Adsorptive Transcytosis [PDF]
Adsorptive-mediated transcytosis (AMT) provides a means for brain delivery of medicines across the blood-brain barrier (BBB). The BBB is readily equipped for the AMT process: it provides both the potential for binding and uptake of cationic molecules to the luminal surface of endothelial cells, and then for exocytosis at the abluminal surface.
Françoise, Hervé +2 more
openaire +2 more sources
Pneumococcal Encounter With the Blood–Brain Barrier Endothelium
Meningitis, the inflammation of the protective membrane surrounding the brain and spinal cord (known as meninges), is a condition associated with high mortality rates and permanent neurological sequelae in a significant proportion of survivors.
Anjali Anil, Anirban Banerjee
doaj +1 more source

